Abstract

Background and Aims

Haemodialysis is the most commoly used replacement therapy for chronic kidney disease. We are looking for new solutions to remove solutes in the middle to high molecular weight range. Our objective is to evaluate and compare the purification of small and middle to high molecular weight between 15-45 KDa with Haemodyafiltration On Line postdilutional (HDF-OL-post) technique, Haemodialysis High-Flux (HD-HF) and Haemodialysis Expanded (HDx) using specific high permeability membranes: in the first two techniques polyphenylene membranes (1.7m2) and in the HDx technique cut point membranes PAEs/PVP (1.7 m2).

Method

10 chronic prevalent patients on haemodialysis, older than 18 years, without diuresis and stable, 60% males. Mean age 65.3±17.47 years. Time in HD, mean 49.5 months. Etiologies: 20% NAE, 30% ND, 10 % Glomerulopathies, 40% unaffiliated. Vascular Accesses: 50% FAVn, 20% FAVp, 30% CVC-T. They were evaluated for three consecutive weeks with analytics in the intermediate session, modifying the technique and the membrane, keeping the dialysis patient stable. Post-dialysis concentrations of solutes in the middle to high molecular weight range were corrected in relation to haemoconcentration. A comparison of the reduction percentages (RP%) of various molecules was performed. The possible normal distribution was studied in the continuous variables with the Shapiro-Wilk test and the comparison of means using the t-Student or Wilconson test as the most appropriate. SPSS statistical program 17.0.

Results

No serious adverse events or allergies were recorded. The comparative results between the three techniques are shown in the figure 1.

Conclusion

The mean reduction of medium molecules (β2-microglobulin, cystatin-C) was not lower in HDx compared to HDF-OL-post. From 20 KDa there is no greater capacity to reduce solutes in HDx in our sample than in the other techniques. Between the three techniques, the HDF-Ol-post is the one that shows a higher percentage of mean reduction of α1-acid glycoprotein and albumin.

HDF-OL-POST Polyphenylene 1.7 m2HD-HF Polyphenylene 1.7 m2HDxPAES/PVP 1.7 m2HDF-OL-POST vs HD-HFHDF-OL-POST vs HDxHD-HF vs HDx
Qb (ml/min)335342,5340n.sn.sn.s
KT (l)44,97±2,4845,29±2,2649,35±2,57n.sp=0,001p=0,001
KT//V1,57±0,241,52±0,191,74±0,26n.sp=0,009p=0,003
URP %73,23±5,3172,09±4,3476,61±4,58p<0.05p=0,003p< 0,001
Vol. inf post (l)

21±2,47

(21- 27,3)

-----

Creatinine

(RP%)

66,00±5,3763,46±5,0967,03±4,41n.sn.sp=0,002
Phosforus (RP%)48,18±17,7153,61±8,4355,98±8,30n.sn.sn.s

Vitamin B12

(RP%)

1,53±10,196,17±5,275,13±7,03n.sn.sn.s
ß 2 microglobulin (RP%)76,14±10,5178,33±1,4481,26±3,05n.sn.sp=0,01

CystatinC

(RP%)

77,44±6,9572,39±7,5776,08±6,08p<0,001n.sp=0,01

Prolactin

(RP%)

71,36±14,1166,69±5,5462,58±8,9n.sn.s (p=0,055)p=0,03

Alfa 1 acid glycoprotein

(RP%)

42,50±9,9615,37±4,358,79±7,2p<0,001p=0,008p<0,001

Albumin

(RP%)

14,44±8,478,62±5,938,1±4,69p=0,014n.s (p=0,069)n.s
HDF-OL-POST Polyphenylene 1.7 m2HD-HF Polyphenylene 1.7 m2HDxPAES/PVP 1.7 m2HDF-OL-POST vs HD-HFHDF-OL-POST vs HDxHD-HF vs HDx
Qb (ml/min)335342,5340n.sn.sn.s
KT (l)44,97±2,4845,29±2,2649,35±2,57n.sp=0,001p=0,001
KT//V1,57±0,241,52±0,191,74±0,26n.sp=0,009p=0,003
URP %73,23±5,3172,09±4,3476,61±4,58p<0.05p=0,003p< 0,001
Vol. inf post (l)

21±2,47

(21- 27,3)

-----

Creatinine

(RP%)

66,00±5,3763,46±5,0967,03±4,41n.sn.sp=0,002
Phosforus (RP%)48,18±17,7153,61±8,4355,98±8,30n.sn.sn.s

Vitamin B12

(RP%)

1,53±10,196,17±5,275,13±7,03n.sn.sn.s
ß 2 microglobulin (RP%)76,14±10,5178,33±1,4481,26±3,05n.sn.sp=0,01

CystatinC

(RP%)

77,44±6,9572,39±7,5776,08±6,08p<0,001n.sp=0,01

Prolactin

(RP%)

71,36±14,1166,69±5,5462,58±8,9n.sn.s (p=0,055)p=0,03

Alfa 1 acid glycoprotein

(RP%)

42,50±9,9615,37±4,358,79±7,2p<0,001p=0,008p<0,001

Albumin

(RP%)

14,44±8,478,62±5,938,1±4,69p=0,014n.s (p=0,069)n.s
HDF-OL-POST Polyphenylene 1.7 m2HD-HF Polyphenylene 1.7 m2HDxPAES/PVP 1.7 m2HDF-OL-POST vs HD-HFHDF-OL-POST vs HDxHD-HF vs HDx
Qb (ml/min)335342,5340n.sn.sn.s
KT (l)44,97±2,4845,29±2,2649,35±2,57n.sp=0,001p=0,001
KT//V1,57±0,241,52±0,191,74±0,26n.sp=0,009p=0,003
URP %73,23±5,3172,09±4,3476,61±4,58p<0.05p=0,003p< 0,001
Vol. inf post (l)

21±2,47

(21- 27,3)

-----

Creatinine

(RP%)

66,00±5,3763,46±5,0967,03±4,41n.sn.sp=0,002
Phosforus (RP%)48,18±17,7153,61±8,4355,98±8,30n.sn.sn.s

Vitamin B12

(RP%)

1,53±10,196,17±5,275,13±7,03n.sn.sn.s
ß 2 microglobulin (RP%)76,14±10,5178,33±1,4481,26±3,05n.sn.sp=0,01

CystatinC

(RP%)

77,44±6,9572,39±7,5776,08±6,08p<0,001n.sp=0,01

Prolactin

(RP%)

71,36±14,1166,69±5,5462,58±8,9n.sn.s (p=0,055)p=0,03

Alfa 1 acid glycoprotein

(RP%)

42,50±9,9615,37±4,358,79±7,2p<0,001p=0,008p<0,001

Albumin

(RP%)

14,44±8,478,62±5,938,1±4,69p=0,014n.s (p=0,069)n.s
HDF-OL-POST Polyphenylene 1.7 m2HD-HF Polyphenylene 1.7 m2HDxPAES/PVP 1.7 m2HDF-OL-POST vs HD-HFHDF-OL-POST vs HDxHD-HF vs HDx
Qb (ml/min)335342,5340n.sn.sn.s
KT (l)44,97±2,4845,29±2,2649,35±2,57n.sp=0,001p=0,001
KT//V1,57±0,241,52±0,191,74±0,26n.sp=0,009p=0,003
URP %73,23±5,3172,09±4,3476,61±4,58p<0.05p=0,003p< 0,001
Vol. inf post (l)

21±2,47

(21- 27,3)

-----

Creatinine

(RP%)

66,00±5,3763,46±5,0967,03±4,41n.sn.sp=0,002
Phosforus (RP%)48,18±17,7153,61±8,4355,98±8,30n.sn.sn.s

Vitamin B12

(RP%)

1,53±10,196,17±5,275,13±7,03n.sn.sn.s
ß 2 microglobulin (RP%)76,14±10,5178,33±1,4481,26±3,05n.sn.sp=0,01

CystatinC

(RP%)

77,44±6,9572,39±7,5776,08±6,08p<0,001n.sp=0,01

Prolactin

(RP%)

71,36±14,1166,69±5,5462,58±8,9n.sn.s (p=0,055)p=0,03

Alfa 1 acid glycoprotein

(RP%)

42,50±9,9615,37±4,358,79±7,2p<0,001p=0,008p<0,001

Albumin

(RP%)

14,44±8,478,62±5,938,1±4,69p=0,014n.s (p=0,069)n.s
This content is only available as a PDF.
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://dbpia.nl.go.kr/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

Comments

0 Comments
Submit a comment
You have entered an invalid code
Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.